Document is current
Any future updates will be listed below
-
Authors
Xing, Chengguo
Malaty, John
Malham, Melissa Bou
Nehme, Anna Maria Abi
Freeman, Breanne
Huo, Zhiguang
Firpi-Morrel, Roberto
Salloum, Ramzi G. https://orcid.org/0000-0002-8139-2418
-
Funding
Funding for this research was provided by:
Florida Department of Health James and Esther King Biomedical Research Program (21K11)
- License Information
-
More Information
Article History
Received: 7 November 2022
Accepted: 6 January 2023
First Online: 18 January 2023
Declarations
:
: This study was approved by the University of Florida IRB on 11/17/2021 under IRB number 202101885 (IRB of Record: UF IRB-01) and is currently registered in the Clinical Trials Registry with the identifier: NCT05081882. Written informed consent will be obtained from all participants before randomization and intervention.
: Not applicable.
: The trial will evaluate AB-free kava’s potential to help adults who smoke reduce tobacco use and risk of lung cancer. The AB-free kava product to be evaluated is developed by Thorne, based on the IPs owned by Kuality Herbceutics (KH). KH has an estimated value of $400,000 on the basis of the IP and the investment to date, which is to support IP protection. There is no profit or product from KH yet. Chengguo Xing owns 55% of the stock of KH. He also provides consultation to KH for its strategy on development.
